News

Retina Update: Potential Biomarker for DME Proposed

Combined Treatment for PDR: Sequence Matters

Susvimo Implant to Return to the Market

Risk of PDR and DME with Popular Weight-loss Drugs

Study Analyzes Spending on Anti-VEGF Injections

Popular Alzheimer's Drug May Help Prevent AMD

Calling out retina’s ‘head-in-the-sand’ approach to mental health and neovascular AMD

Five events make for a busy summer in retina

In the Lucentis biosimilars wars, there are no winners so far

Study reports potential of OCT to identify vascular damage in severe COVID-19

With FDA approval, pegcetacoplan launches with high awareness—and a few questions

Why are ophthalmologists a definite maybe about biosimilars? Survey provides answers

A deeper dive into anti-VEGF loss to follow-up: Study identifies risk factors

Where are the women in retina? Not at the podium, study reports

Bevacizumab first, aflibercept second cost-effective for DME, Protocol AC finds

With Byooviz, Biogen takes a leap on pricing first U.S. retina biosimilar

New DME treatment trial targets underrepresented populations

A deeper dive into why DAZZLE results of KSI-301 in nAMD ‘disappointed’

Retina Update: Is Vabysmo the next $1 billion anti-VEGF?

Retina Update: Market forces may be gathering to exert price pressures on anti-VEGF drugs

Load More